Agency Forms Undergoing Paperwork Reduction Act Review, 46117-46119 [2024-11589]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 103 / Tuesday, May 28, 2024 / Notices
19.To such recipients and under such
circumstances and procedures as are
mandated by federal statute.
POLICIES AND PRACTICES FOR STORAGE OF
RECORDS:
Records in this system are stored in
electronic and/or paper format.
Electronic records are stored in
computerized databases on the
Commission’s servers as well as in
secured FedRAMP-certified cloud
environments. Paper records are stored
in locked file rooms and/or file cabinets
located in the Office of the General
Counsel.
POLICIES AND PRACTICES FOR RETRIEVAL OF
RECORDS:
Records are indexed and retrieved by
a unique tracking number assigned to
the request or appeal. Records are also
retrieved by the requestor’s or
appellant’s name, date, and the subject
of the request.
POLICIES AND PRACTICES FOR RETENTION AND
DISPOSAL OF RECORDS:
Records in this system are retained
and disposed of in accordance with the
General Records Schedules issued by
the National Archives and Records
Administration.
khammond on DSKJM1Z7X2PROD with NOTICES
RECORD ACCESS PROCEDURES:
Individuals seeking to determine
whether this system of records contains
information about themselves or seeking
access to records about themselves in
this system of records should address
written inquiries to: Executive Director,
18:43 May 24, 2024
Jkt 262001
Individuals contesting the content of
records about themselves contained in
this system of records should address
written inquiries to: Executive Director,
FMSHRC, 1331 Pennsylvania Avenue
NW, Suite 520N, Washington, DC
20004–1710. For an explanation on the
specific procedures for contesting the
contents of a record, refer to FMSHRC’s
regulations contained in 29 CFR part
2705.
NOTIFICATION PROCEDURE:
Individuals seeking notification of
any records about themselves contained
in this system of records should address
written inquiries to: Executive Director,
FMSHRC, 1331 Pennsylvania Avenue
NW, Suite 520N, Washington, DC
20004–1710. For an explanation on the
specific procedures for sending a
notification request, refer to FMSHRC’s
regulations contained in 29 CFR part
2705.
None.
Records are safeguarded in a secured
environment. The building where the
records are stored has security cameras
and security guard service. Access to the
Commission’s office in Washington, DC
may be gained only by using an
electronic key, which is provided only
to Commission personnel. Paper records
are kept in limited access areas during
duty hours and in locked file cabinets
and/or locked offices at all other times.
Access is limited to those personnel
whose official duties require access.
Computerized records are safeguarded
through use of information technology
security controls, as dictated by the
Federal Information Security
Modernization Act (FISMA) and the
National Institute of Standards and
Technology (NIST), and access is
limited to those personnel whose
official duties require access.
Contractors and other recipients
providing services to the Commission
shall be required to maintain the same
or equivalent safeguards.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2024–11648 Filed 5–24–24; 8:45 am]
BILLING CODE P
CONTESTING RECORD PROCEDURES:
EXEMPTIONS CLAIMED FOR THE SYSTEM:
ADMINISTRATIVE, TECHNICAL, AND PHYSICAL
SAFEGUARDS:
VerDate Sep<11>2014
FMSHRC, 1331 Pennsylvania Avenue
NW, Suite 520N, Washington, DC
20004–1710. For an explanation on how
such requests should be drafted, refer to
FMSHRC’s regulations contained in 29
CFR part 2705.
46117
HISTORY:
None.
Dated: April 5, 2024.
Stacey George,
Chief FOIA Officer and Acting Senior Agency
Official for Privacy, Federal Mine Safety and
Health Review Commission.
[FR Doc. 2024–11625 Filed 5–24–24; 8:45 am]
BILLING CODE 6735–01–P
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies;
Correction
This notice corrects a notice (FR Doc.
2024–11345) published on page 44980
in the third column of the issue for
Wednesday, May 22, 2024.
Under A. Federal Reserve Bank of
New York, entry 1 is corrected to read
as follows:
1. Hanover Bancorp, Inc., Mineola,
New York (a Maryland corporation); to
become a bank holding company by
acquiring Hanover Bancorp, Inc.,
Mineola, New York (a New York
corporation), and thereby indirectly
acquiring Hanover Community Bank,
Garden City Park, New York.
Comments on this application must
be received by June 27, 2024.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–24–0931]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled ‘‘Blood Lead
Surveillance System (BLSS)’’ to the
Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on November 27, 2023 to obtain
comments from the public and affected
agencies. CDC received one comment
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
E:\FR\FM\28MYN1.SGM
28MYN1
46118
Federal Register / Vol. 89, No. 103 / Tuesday, May 28, 2024 / Notices
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Blood Lead Surveillance System
(BLSS) (OMB Control No. 0920–0931,
Exp. 07/31/2024)—Extension—National
Center for Environmental Health
(NCEH), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
This is a request for a three-year
Extension for an existing Paperwork
Reduction Act (PRA) clearance titled
‘‘Blood Lead Surveillance System
(BLSS)’’ (OMB Control No.0920–0931,
Exp. 07/31/2024). The National Center
for Environmental Health (NCEH) is
leading this data collection conducted
by for two Centers for Disease Control
and Prevention (CDC) programs; one for
childhood blood lead surveillance by
NCEH and another for adult blood lead
surveillance by the National Institute for
Occupational Safety and Health
(NIOSH).
The goal of the NCEH Childhood
Blood Lead Surveillance (CBLS)
Program is to support blood lead
screening and to promote primary
prevention of exposure to lead. The
CBLS Program also supports secondary
prevention of adverse health effects
when lead exposures occur in children,
through improved program management
and oversight in respondent
jurisdictions.
The goal of the NIOSH Adult Blood
Lead Epidemiology and Surveillance
(ABLES) Program is to build state
capacity for adult blood lead
surveillance programs to measure trends
in adult blood lead levels and to prevent
lead over-exposures.
NCEH has a five-year cooperative
agreement, titled ‘‘Childhood Lead
Poisoning Prevention and Surveillance
of Blood Lead Levels in Children’’
(Funding Opportunity Announcement
[FOA] No. CDC–RFA–EH21–2102). The
first two years of this ICR will extend
from FY24 through FY26, and thus will
be covered for two-thirds of the ICR
three-year period, while funding for the
third year of this ICR will be determined
in the future. Data submission to the
ABLES Program is voluntary and
completed through data sharing
agreements with state agencies or their
bona fide agents.
Blood lead surveillance over the
human lifespan is covered under this
single ICR, specifically for children
younger than 16 years through CBLS at
NCEH, and for adults 16 years and
older, through ABLES at NIOSH. Over
the past several decades there have been
substantial efforts in environmental lead
abatement, improved protection from
occupational lead exposure, and a
reduction in the prevalence of
population blood lead levels (BLLs) over
time. The U.S. population BLLs have
substantially decreased over the last
four decades. For example, the CDC has
reported the 1976–1980 U.S. mean BLL
in children six months to five years was
16.0 micrograms per deciliter (mcg/dL),
and 14.1 mcg/dL among adults 18 to 74
years. More recently, the CDC reported
the 2009–2010 U.S. BLL geometric
means among children one to five years
and among adults 20 years and older as
1.2 mcg/dL for both age groups. In 2012,
the National Toxicology Program (NTP)
concluded that there is sufficient
evidence that even BLLs less than 5
mcg/dL are associated with adverse
health effects in both children and
adults. Despite the reduction in the
overall population BLL over four
decades, lead exposures continue to
occur at unacceptable levels for
individuals in communities and
workplaces across the nation.
Surveillance will continue through
CBLS and ABLES to identify
individuals with BLLs greater than most
children who may need follow-up.
Surveillance can also help prioritize
communities for primary prevention of
lead exposure and expanding blood lead
testing. As of October 2021, NCEH
defines its Blood Lead Reference Value
(BLRV) for children at 3.5 mcg/dL.
NIOSH defines an elevated BLLs as
greater than or equal to 5 mcg/dL for
adults.
Respondents are defined as state,
local, and territorial health departments
with lead poisoning prevention
programs. The estimated annual time
burden for NCEH CBLS is 1,058 hours.
The estimated annual time burden for
NIOSH ABLES is 280 hours. In total,
CDC is requesting approval for a total
annual time burden of 1,338 hours.
khammond on DSKJM1Z7X2PROD with NOTICES
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
State, Local and Territorial Health Departments, or their
Bona Fide Agents.
CBLS Variables (ASCII Text
Files).
CBLS Aggregate Records
Form (Excel).
ABLES Case Records Form
and Brief Narrative Report.
ABLES Aggregate Records
Form and Brief Narrative
Report.
VerDate Sep<11>2014
18:43 May 24, 2024
Jkt 262001
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Number of
respondents
Type of respondents
E:\FR\FM\28MYN1.SGM
Average
burden per
response
(in hours)
66
4
4
1
1
2
32
1
8
8
1
3
28MYN1
Federal Register / Vol. 89, No. 103 / Tuesday, May 28, 2024 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–11589 Filed 5–24–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day-24–24FS; Docket No. CDC–2024–
0038]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comments on a proposed information
collection titled Needle Exchange
Utilization Survey (NEXUS). This data
collection is being created to develop a
surveillance system to monitor drug use,
prevention behaviors, and the infectious
disease consequences of drug use in
select urban and non-urban areas of the
U.S.
DATES: CDC must receive written
comments on or before July 29, 2024.
ADDRESSES: You may submit comments
identified by Docket No. CDC–2024–
0038 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:43 May 24, 2024
Jkt 262001
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7118; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION:
Under the Paperwork Reduction Act
of 1995 (PRA) (44 U.S.C. 3501–3520),
Federal agencies must obtain approval
from the Office of Management and
Budget (OMB) for each collection of
information they conduct or sponsor. In
addition, the PRA also requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each new proposed
collection, each proposed extension of
the existing collection of information,
and each reinstatement of previously
approved information collection before
submitting the collection to the OMB for
approval. To comply with this
requirement, we are publishing this
notice of a proposed data collection as
described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of collecting
information on those to respond,
including using appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic responses;
and
5. Assess information collection costs.
Proposed Project
Needle Exchange Utilization Survey
(NEXUS)—New—National Center for
HIV, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
The purpose of the Needle Exchange
Utilization Survey (NEXUS) is to
develop a surveillance system to
monitor drug use, prevention behaviors,
and the infectious disease consequences
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
46119
of drug use in 6–15 select urban and
non-urban areas of the U.S. that the
opioid crisis has impacted. Such a
surveillance system is needed to inform
prevention efforts and policy. The
specific objectives of the project are to
assess the following among persons who
inject drugs who are recruited in syringe
services programs (SSPs) and their peers
who use drugs through peer-driven
recruitment: (1) drug use and sexual
behaviors, injection risk networks,
receipt of prevention services, and
barriers to prevention and care; and (2)
the prevalence of HIV and hepatitis C
(HCV) infections.
The project will involve a two-stage
sampling approach. First, up to 15 SSPs
will be selected to ensure geographic
diversity and representation of key
program characteristics, such as the
syringe distribution model (needs-based
vs. all others) and length in operation
(<5 years, ≥5 years). Second, SSP
clients, the majority who are persons
who inject drugs (PWID), and their
peers who use drugs will be recruited
through a combination of direct
recruitment at each SSP and peer-driven
recruitment to partake in a survey and
HCV and HIV testing.
Clients of SSPs and their peers who
meet eligibility criteria will complete a
survey using an Electronic Data Capture
system, a secure web-based application
for administering online surveys. The
survey will include questions on drug
use and sexual behaviors, injection risk
networks, drug treatment history,
history of drug use-related adverse
health outcomes, experiences with law
enforcement, HIV and HCV testing
experience, and use of prevention and
health care services. Lastly, participants
will be offered anonymous HIV and
HCV testing in conjunction with the
survey, which they may refuse with no
effect on participation in the survey.
Data from NEXUS will be used to
inform the planning and evaluation of
prevention programs at the local and
national levels that aim to reduce
adverse health outcomes due to
injection and non-injection drug use
and to contribute to the overall opioid
crisis response efforts. Data from
NEXUS will also be used for an ongoing
surveillance system in the U.S. to
monitor trends in drug use and the
infectious disease consequences of drug
use.
Approximately 6,000 individuals will
complete the eligibility screener. Our
target population is 300 participants per
site or 4,500 for up to 15 sites. We
anticipate that, on average, 25% or
1,499 persons (for up to 15 SSPs) will
not be interested in completing a
questionnaire, yielding a maximum of
E:\FR\FM\28MYN1.SGM
28MYN1
]]>Agencies
[Federal Register Volume 89, Number 103 (Tuesday, May 28, 2024)]
[Notices]
[Pages 46117-46119]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11589]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-24-0931]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Blood Lead Surveillance System (BLSS)'' to
the Office of Management and Budget (OMB) for review and approval. CDC
previously published a ``Proposed Data Collection Submitted for Public
Comment and Recommendations'' notice on November 27, 2023 to obtain
comments from the public and affected agencies. CDC received one
comment related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy
[[Page 46118]]
of the information collection plan and instruments, call (404) 639-
7570. Comments and recommendations for the proposed information
collection should be sent within 30 days of publication of this notice
to www.reginfo.gov/public/do/PRAMain. Find this particular information
collection by selecting ``Currently under 30-day Review--Open for
Public Comments'' or by using the search function. Direct written
comments and/or suggestions regarding the items contained in this
notice to the Attention: CDC Desk Officer, Office of Management and
Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Blood Lead Surveillance System (BLSS) (OMB Control No. 0920-0931,
Exp. 07/31/2024)--Extension--National Center for Environmental Health
(NCEH), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
This is a request for a three-year Extension for an existing
Paperwork Reduction Act (PRA) clearance titled ``Blood Lead
Surveillance System (BLSS)'' (OMB Control No.0920-0931, Exp. 07/31/
2024). The National Center for Environmental Health (NCEH) is leading
this data collection conducted by for two Centers for Disease Control
and Prevention (CDC) programs; one for childhood blood lead
surveillance by NCEH and another for adult blood lead surveillance by
the National Institute for Occupational Safety and Health (NIOSH).
The goal of the NCEH Childhood Blood Lead Surveillance (CBLS)
Program is to support blood lead screening and to promote primary
prevention of exposure to lead. The CBLS Program also supports
secondary prevention of adverse health effects when lead exposures
occur in children, through improved program management and oversight in
respondent jurisdictions.
The goal of the NIOSH Adult Blood Lead Epidemiology and
Surveillance (ABLES) Program is to build state capacity for adult blood
lead surveillance programs to measure trends in adult blood lead levels
and to prevent lead over-exposures.
NCEH has a five-year cooperative agreement, titled ``Childhood Lead
Poisoning Prevention and Surveillance of Blood Lead Levels in
Children'' (Funding Opportunity Announcement [FOA] No. CDC-RFA-EH21-
2102). The first two years of this ICR will extend from FY24 through
FY26, and thus will be covered for two-thirds of the ICR three-year
period, while funding for the third year of this ICR will be determined
in the future. Data submission to the ABLES Program is voluntary and
completed through data sharing agreements with state agencies or their
bona fide agents.
Blood lead surveillance over the human lifespan is covered under
this single ICR, specifically for children younger than 16 years
through CBLS at NCEH, and for adults 16 years and older, through ABLES
at NIOSH. Over the past several decades there have been substantial
efforts in environmental lead abatement, improved protection from
occupational lead exposure, and a reduction in the prevalence of
population blood lead levels (BLLs) over time. The U.S. population BLLs
have substantially decreased over the last four decades. For example,
the CDC has reported the 1976-1980 U.S. mean BLL in children six months
to five years was 16.0 micrograms per deciliter (mcg/dL), and 14.1 mcg/
dL among adults 18 to 74 years. More recently, the CDC reported the
2009-2010 U.S. BLL geometric means among children one to five years and
among adults 20 years and older as 1.2 mcg/dL for both age groups. In
2012, the National Toxicology Program (NTP) concluded that there is
sufficient evidence that even BLLs less than 5 mcg/dL are associated
with adverse health effects in both children and adults. Despite the
reduction in the overall population BLL over four decades, lead
exposures continue to occur at unacceptable levels for individuals in
communities and workplaces across the nation. Surveillance will
continue through CBLS and ABLES to identify individuals with BLLs
greater than most children who may need follow-up. Surveillance can
also help prioritize communities for primary prevention of lead
exposure and expanding blood lead testing. As of October 2021, NCEH
defines its Blood Lead Reference Value (BLRV) for children at 3.5 mcg/
dL. NIOSH defines an elevated BLLs as greater than or equal to 5 mcg/dL
for adults.
Respondents are defined as state, local, and territorial health
departments with lead poisoning prevention programs. The estimated
annual time burden for NCEH CBLS is 1,058 hours. The estimated annual
time burden for NIOSH ABLES is 280 hours. In total, CDC is requesting
approval for a total annual time burden of 1,338 hours.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondents Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
State, Local and Territorial Health CBLS Variables (ASCII 66 4 4
Departments, or their Bona Fide Text Files).
Agents.
CBLS Aggregate Records 1 1 2
Form (Excel).
ABLES Case Records Form 32 1 8
and Brief Narrative
Report.
ABLES Aggregate Records 8 1 3
Form and Brief
Narrative Report.
----------------------------------------------------------------------------------------------------------------
[[Page 46119]]
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-11589 Filed 5-24-24; 8:45 am]
BILLING CODE 4163-18-P
